Adipex-P 37.5mg

Short-Term Pharmacological Support for Weight Management

Adipex-P® 37.5mg tablets contain phentermine hydrochloride, a centrally-acting sympathomimetic amine that has been used as a short-term adjunct in weight management for decades. As a Schedule IV controlled substance with potential for abuse and dependence, Adipex-P® is indicated only for short-term use (a few weeks) as part of a comprehensive weight reduction program that includes caloric restriction, exercise, and behavioral modification. The medication works primarily by stimulating the release of norepinephrine in the hypothalamus, leading to appetite suppression and increased energy expenditure. The 37.5mg strength represents the most commonly prescribed dosage, typically administered as a single daily dose in the morning to minimize potential insomnia while providing appetite control throughout the day.

Appetite Suppression with Specific Limitations and Considerations

Phentermine, the active ingredient in Adipex-P®, produces its appetite-suppressing effects through central nervous system stimulation, which can also lead to increased alertness, energy, and potential side effects characteristic of sympathomimetic agents. Due to its mechanism of action and potential for tolerance development, treatment is strictly limited to short-term use—typically 12 weeks or less—as its effectiveness for weight management beyond this period has not been established, and the risk of dependence increases with longer use. Patients typically experience reduced hunger, decreased food cravings, and improved ability to adhere to reduced-calorie diets during the treatment period. It is crucial to understand that Adipex-P® is not a long-term solution for weight management but rather a temporary tool to help initiate lifestyle changes that must be sustained after medication discontinuation.

Key Features of Adipex-P® 37.5mg:

• Short-Term Appetite Suppression: Provides pharmacological support to help patients adhere to reduced-calorie diets during the initial phase of weight management.

• Once-Daily Morning Dosing: Typically administered as a single 37.5mg tablet in the morning to control appetite throughout the day while minimizing sleep disruption.

• Proven Historical Use: Has been used in weight management for over 60 years with well-characterized efficacy and safety profiles when used as directed.

• Comprehensive Program Component: Intended only as an adjunct to comprehensive weight management including diet, exercise, and behavior modification.

• Specific Time Limitation: FDA-approved for short-term use only (a few weeks) due to potential for tolerance and dependence.

Clinical Protocol & Critical Safety Information:

• Dosage Regimen: One 37.5mg tablet daily, typically administered in the morning to avoid interference with sleep. May be taken with or without food.

• Treatment Duration: Short-term use only (a few weeks). The safety and efficacy beyond 12 weeks have not been established.

• Important Contraindications:

  • History of cardiovascular disease (coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)

  • Hyperthyroidism

  • Glaucoma

  • Agitated states

  • History of drug abuse

  • During or within 14 days following MAO inhibitor therapy

  • Pregnancy or nursing

• Common Side Effects: Dry mouth, insomnia, headache, dizziness, tremors, restlessness, nervousness, constipation, and increased heart rate or blood pressure.

• Serious Risks: Primary pulmonary hypertension, valvular heart disease, dependence, psychosis, seizures, and cardiovascular events.

• Drug Interactions: Significant interactions with MAO inhibitors, other weight loss medications, SSRIs, SNRIs, and other sympathomimetic agents.

• Abuse Potential: Schedule IV controlled substance with potential for abuse, dependence, and tolerance. Should be prescribed cautiously with careful patient screening.

• Monitoring Requirements: Regular monitoring of blood pressure, heart rate, and cardiovascular symptoms is essential. Patients should be assessed for signs of dependence or abuse.